双能CT预测晚期肺腺癌化疗疗效的预测因素
研究前瞻性纳入90例不可切除的IIIB或IV期肺腺癌患者,化疗前接受双能CT检查,按RECIST 1.1分为应答组38例与非应答组52例。应答组平均碘浓度显著高于非应答组(1.81±0.51 vs 1.33±0.76 mg/ml,p<0.001);多因素分析显示EGFR突变(OR 3.116,95%CI 1.182-8.213,p=0.019)与碘浓度(OR 1.112,95%CI 1.034-1.196,p=0.006)是化疗应答的显著预测因素。
要点
- 化疗前双能CT碘浓度较高者更可能获得RECIST应答
- EGFR突变与碘浓度均为化疗应答的独立预测因素
- 碘浓度OR 1.112(95%CI 1.034-1.196,p=0.006)
核心结论
- 基于碘浓度定量分析的双能CT可用于预测晚期肺腺癌患者的化疗效果。
研究设计与样本
- 前瞻性研究,共纳入90例不可切除肺腺癌患者(男59例、女31例,年龄61.4±12.3岁,范围23-85岁),TNM分期IIIB或IV期,化疗前接受双能CT检查,以RECIST 1.1版指南分为应答组(CR或PR)与非应答组(SD或PD),采用logistic回归模型评估化疗应答的预测因素。
关键影像表现/征象
- 应答组平均碘浓度显著高于非应答组(1.81±0.51 vs 1.33±0.76 mg/ml,p<0.001)。
诊断标准与关键数值
- 以RECIST 1.1版指南分组:应答组为CR或PR,非应答组为SD或PD,90例中应答38例、非应答52例。
- 多因素分析中EGFR突变预测化疗应答的OR为3.116(95%CI 1.182-8.213,p=0.019)。
- 多因素分析中碘浓度预测化疗应答的OR为1.112(95%CI 1.034-1.196,p=0.006)。
临床应用与阅片要点
- 作者结论认为,基于碘浓度测量的双能CT定量分析方法可用于预测晚期肺腺癌患者的化疗效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to investigate whether the quantitative parameters of dual-energy computed tomography (DECT) can predict the effects of chemotherapy in advanced adenocarcinoma based on the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
MATERIALS AND METHODS: A total of 90 patients (59 males, 31 females, age 61.4 ± 12.3 (23-85)) with unresectable lung adenocarcinoma (TNM stage IIIB or IV) who underwent DECT before chemotherapy were prospectively included in this study. By comparing baseline studies with the best response achieved during 1 st line chemotherapy, patients were divided into two groups according to RECIST (version 1.1) guidelines as follows; responders (CR or PR) and non-responders (SD or PD). Quantitative measurements were performed on baseline DECT, and a logistic regression model was used to evaluate predictive factors for a response to chemotherapy.
RESULTS: Among 90 patients, 38 were categorized as responders, while 52 patients were non-responders. The mean iodine concentration measurements were significantly higher in responders compared with non-responders (1.81 ± 0.51 vs 1.33 ± 0.76 mg/ml, p < 0.001). On multivariate analysis, EGFR mutation (odds ratio (OR): 3.116, 95% confidential interval (CI):1.182-8.213, p = .019) and iodine concentration (OR: 1.112, 95% CI:1.034-1.196, p = .006) were found to be significant for predicting a treatment response.
CONCLUSIONS: Dual-energy CT using a quantitative analytic method based on iodine concentration measurements can be used to predict the effects of chemotherapy in patients with advanced adenocarcinoma.
引用
- Hong SR, Hur J, Moon YW, et al. Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. Eur J Radiol. 2018. PMID: 29571784. doi:10.1016/j.ejrad.2018.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。